These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7478404)

  • 41. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
    Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y
    Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiolabelled peptides: now and the future.
    Thakur ML
    Nucl Med Commun; 1995 Sep; 16(9):724-32. PubMed ID: 7478404
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.
    Bartholomä M; Valliant J; Maresca KP; Babich J; Zubieta J
    Chem Commun (Camb); 2009 Feb; (5):493-512. PubMed ID: 19283279
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current use and future potential of organometallic radiopharmaceuticals.
    Schibli R; Schubiger PA
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1529-42. PubMed ID: 12397472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Methods of leukocyte radionuclide labeling and the potentials for using labelled leukocytes in medicine].
    Vorob'eva EN
    Med Radiol (Mosk); 1981 Nov; 26(11):81-6. PubMed ID: 7033713
    [No Abstract]   [Full Text] [Related]  

  • 49. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer.
    Giblin MF; Veerendra B; Smith CJ
    In Vivo; 2005; 19(1):9-29. PubMed ID: 15796153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer.
    Okarvi SM
    Cancer Treat Rev; 2008 Feb; 34(1):13-26. PubMed ID: 17870245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals: an overview.
    Okarvi SM
    Nucl Med Commun; 1999 Dec; 20(12):1093-112. PubMed ID: 10664991
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.